Alnylam Pharmaceuticals, Inc. reiterated earnings guidance for the full year 2024. For the period, the company expects combined net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO to be $1,400 million to $1,500 million and net revenues from collaborations and royalties to be $325 million to $425 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
149.4 USD | -1.20% | -0.71% | -21.95% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.95% | 18.9B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B | |
-6.26% | 11.42B | |
+2.05% | 10.14B |
- Stock Market
- Equities
- ALNY Stock
- News Alnylam Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024